Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases - PubMed (original) (raw)
Review
doi: 10.4161/cc.7.23.7122. Epub 2008 Dec 4.
Affiliations
- PMID: 19029809
- DOI: 10.4161/cc.7.23.7122
Review
Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases
Gaetano Romano et al. Cell Cycle. 2008 Dec.
Abstract
Cyclin-dependent kinase 9 (Cdk9) is a cdc2-like serine/threonine kinase. The so-called Cdk9-related pathway comprises two Cdk9 isoforms (Cdk9-42 and Cdk9-55), cyclin T1, cyclin T2a, cyclin T2b and cyclin K. The association between Cdk9 and one of its cyclin partners forms a heterodimer, which is the main component of the positive transcription elongation factor (P-TEFb). The latter stabilizes the elongation process of RNA polymerase II (polII) transcripts. Through the control of RNA polII-mediated gene expression, the Cdk9-related pathway performs an important role in several biological processes, such as cell growth, proliferation, protection from apoptosis and differentiation. Incidentally, the P-TEFb that contains the heterodimer Cdk9-cyclin T1 is also critical for HIV-1 and HIV-2 replication in human cells. A deregulation in the Cdk9-related pathway is associated with various types of human malignancies and cardiomyocytes hypertrophy. On these grounds, the characterization of Cdk9-related pathway deregulation might have a two-fold purpose: (1) the development of novel kinase inhibitors for the treatment of cancer, AIDS and cardiac hypertrophy and (2) a better understanding of the pathogenesis and progression of these maladies.
Similar articles
- CDK9: from basal transcription to cancer and AIDS.
De Falco G, Giordano A. De Falco G, et al. Cancer Biol Ther. 2002 Jul-Aug;1(4):342-7. Cancer Biol Ther. 2002. PMID: 12432243 Review. - Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29.
Zhou M, Huang K, Jung KJ, Cho WK, Klase Z, Kashanchi F, Pise-Masison CA, Brady JN. Zhou M, et al. J Virol. 2009 Jan;83(2):1036-44. doi: 10.1128/JVI.01316-08. Epub 2008 Oct 29. J Virol. 2009. PMID: 18971272 Free PMC article. - Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms.
Shore SM, Byers SA, Dent P, Price DH. Shore SM, et al. Gene. 2005 Apr 25;350(1):51-8. doi: 10.1016/j.gene.2005.01.015. Gene. 2005. PMID: 15780980 - Mechanisms controlling CDK9 activity.
Marshall RM, Grana X. Marshall RM, et al. Front Biosci. 2006 Sep 1;11:2598-613. doi: 10.2741/1994. Front Biosci. 2006. PMID: 16720337 Review. - Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).
Chiu YL, Cao H, Jacque JM, Stevenson M, Rana TM. Chiu YL, et al. J Virol. 2004 Mar;78(5):2517-29. doi: 10.1128/jvi.78.5.2517-2529.2004. J Virol. 2004. PMID: 14963154 Free PMC article.
Cited by
- Functional characterization of a new member of the Cdk9 family in Aspergillus nidulans.
Bathe F, Kempf C, Osmani SA, Osmani AH, Hettinger S, Wohlmann E, Fischer R. Bathe F, et al. Eukaryot Cell. 2010 Dec;9(12):1901-12. doi: 10.1128/EC.00384-09. Epub 2010 Oct 15. Eukaryot Cell. 2010. PMID: 20952582 Free PMC article. - Cell cycle kinases as therapeutic targets for cancer.
Lapenna S, Giordano A. Lapenna S, et al. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907. Nat Rev Drug Discov. 2009. PMID: 19568282 Review. - Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases.
Klein M. Klein M. Pharmaceuticals (Basel). 2023 Mar 31;16(4):519. doi: 10.3390/ph16040519. Pharmaceuticals (Basel). 2023. PMID: 37111276 Free PMC article. - CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas.
Cassandri M, Fioravanti R, Pomella S, Valente S, Rotili D, Del Baldo G, De Angelis B, Rota R, Mai A. Cassandri M, et al. Front Pharmacol. 2020 Aug 13;11:1230. doi: 10.3389/fphar.2020.01230. eCollection 2020. Front Pharmacol. 2020. PMID: 32903585 Free PMC article. Review. - Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N. Cirstea D, et al. Leukemia. 2013 Dec;27(12):2366-75. doi: 10.1038/leu.2013.194. Epub 2013 Jun 28. Leukemia. 2013. PMID: 23807770 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous